M&A - Sage Therapeutics, Inc.

Form Type: 8-K

Filing Date: 2025-01-27

Corporate Action: Acquisition

Type: Update

Accession Number: 000119312525012790

Filing Summary: On January 27, 2025, Sage Therapeutics, Inc. announced through a press release that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The announcement also included the rejection of an unsolicited, non-binding proposal from Biogen Inc. made on January 10, 2025, which sought to acquire all outstanding shares of the Company not owned by Biogen at a price of $7.22 per share. This strategic exploration signifies the Company's openness to explore various options following the acquisition proposal.

Document Link: View Document

Form Type: 8-K

Filing Date: 2025-01-13

Corporate Action: Acquisition

Type: Update

Accession Number: 000119312525004907

Filing Summary: Sage Therapeutics, Inc. received an unsolicited, non-binding acquisition proposal from Biogen Inc. This announcement was made public through a press release dated January 10, 2025. Additionally, the company prepared an updated corporate presentation for investor meetings at the J.P. Morgan Healthcare Conference, which took place on January 12, 2025. The related corporate presentation and press release are included as exhibits in this filing. The proposal from Biogen is a significant event for Sage Therapeutics, indicating potential changes in corporate structure or ownership if pursued further.

Document Link: View Document